Long-term Survival After Radical Prostatectomy for Men with High Gleason Sum in Pathologic Specimen

Overview

Journal Urology

Specialty Urology

Date 2010 Mar 31

PMID 20350749

Citations 17

Authors

Phillip M Pierorazio

Thomas J Guzzo

Misop Han

Trinity J Bivalacqua

Jonathan I Epstein

Edward M Schaeffer

Mark Schoenberg

Patrick C Walsh

Alan W Partin

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the long-term outcomes of patients with high Gleason sum 8-10 at radical prostatectomy (RP) and to identify the predictors of prostate cancer-specific survival (CSS) in this cohort.

Methods: The institutional RP database was queried. A total of 9381 patients with complete follow-up underwent RP from 1982 to 2008. Of these 9381 patients, 1061 had pathologic Gleason sum 8-10 cancer. The patient and prostate cancer characteristics were evaluated. Survival analyses were performed using the Kaplan-Meier method. Univariate and multivariate proportional hazard regression models were created to evaluate the pertinent predictors of CSS (death from, or attributed to, prostate cancer).

Results: The median preoperative prostate-specific antigen level was 7.6 ng/mL; 435 men had clinical Stage T1 tumor, 568 had Stage T2, and 36 had Stage T3. The biopsy Gleason sum was <7, 7, and >7 in 244 (22.3%), 406 (37.2%), and 425 (38.9%) patients, respectively. The median follow-up was 5 years (range 1-23). The actuarial 15-year recurrence-free survival, CSS, and overall survival rate was 20.7%, 57.4%, and 45.4%, respectively. On multivariate analysis, the predictors of poor CSS were pathologic Gleason sum 9-10 and seminal vesicle and lymph node involvement. Patients with pathologic Gleason sum 8 and organ-confined disease had a CSS rate of 89.9% at 15 years.

Conclusions: The results of our study have shown that 80% of the men with Gleason sum 8-10 who undergo RP will have experienced biochemical recurrence by 15 years. However, the CSS rate approached 90% for men with pathologic organ-confined disease. Higher pathologic Gleason sum 9-10 and seminal vesicle and lymph node involvement were independent predictors of worse CSS.

Citing Articles

Anti-Müllerian hormone: a novel biomarker for aggressive prostate cancer? Emerging evidence from a prospective study of radical prostatectomies.

Kontogiannis S, Markantes G, Stamou M, Tsagkarakis M, Mamali I, Giannitsas K Hormones (Athens). 2023; 23(2):297-304.

PMID: 38127275 PMC: 11190032. DOI: 10.1007/s42000-023-00520-z.

Surgical management of high-risk, localized prostate cancer.

Wilkins L, Tosoian J, Sundi D, Ross A, Grimberg D, Klein E Nat Rev Urol. 2020; 17(12):679-690.

PMID: 33173205 DOI: 10.1038/s41585-020-00384-7.

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.

Tilki D, Chen M, Wu J, Huland H, Graefen M, Braccioforte M JAMA Oncol. 2018; 5(2):213-220.

PMID: 30452521 PMC: 6439553. DOI: 10.1001/jamaoncol.2018.4836.

Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis.

Tae B, Cho S, Kim H, Kim C, Kang S, Lee J Sci Rep. 2018; 8(1):10748.

PMID: 30013089 PMC: 6048060. DOI: 10.1038/s41598-018-28566-9.

Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up.

Spratt D, Jackson W, Abugharib A, Tomlins S, Dess R, Soni P Prostate Cancer Prostatic Dis. 2016; 19(3):292-7.

PMID: 27215611 DOI: 10.1038/pcan.2016.18.

References

Kattan M, Wheeler T, Scardino P . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17(5):1499-507. DOI: 10.1200/JCO.1999.17.5.1499. View

Boorjian S, Karnes R, Rangel L, Bergstralh E, Frank I, Blute M . Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2007; 101(3):299-304. DOI: 10.1111/j.1464-410X.2007.07269.x. View

Grossfeld G, Latini D, Lubeck D, Mehta S, Carroll P . Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2002; 169(1):157-63. DOI: 10.1016/S0022-5347(05)64058-X. View

Pound C, Partin A, Epstein J, Walsh P . Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24(2):395-406. DOI: 10.1016/s0094-0143(05)70386-4. View

Lau W, Bergstralh E, Blute M, Slezak J, Zincke H . Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2001; 167(1):117-22. View

Loblaw D, Virgo K, Nam R, Somerfield M, Ben-Josef E, Mendelson D . Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007; 25(12):1596-605. DOI: 10.1200/JCO.2006.10.1949. View

Bolla M, Gonzalez D, Warde P, Dubois J, Mirimanoff R, Storme G . Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337(5):295-300. DOI: 10.1056/NEJM199707313370502. View

Schild S, Wong W, Grado G, Halyard M, Novicki D, Swanson S . The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys. 1996; 34(3):535-41. DOI: 10.1016/0360-3016(95)02161-2. View

Tefilli M, Gheiler E, Tiguert R, Banerjee M, Sakr W, Grignon D . Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate. 1999; 39(1):60-6. DOI: 10.1002/(sici)1097-0045(19990401)39:1<60::aid-pros10>3.0.co;2-u. View

10.

Chodak G, Thisted R, Gerber G, Johansson J, Adolfsson J, Jones G . Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994; 330(4):242-8. DOI: 10.1056/NEJM199401273300403. View

11.

Partin A, Yoo J, Carter H, Pearson J, Chan D, Epstein J . The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150(1):110-4. DOI: 10.1016/s0022-5347(17)35410-1. View

12.

Kattan M, Eastham J, Stapleton A, Wheeler T, Scardino P . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71. DOI: 10.1093/jnci/90.10.766. View

13.

Catalona W, Stein A, Fair W . Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol. 1982; 127(5):919-22. DOI: 10.1016/s0022-5347(17)54132-4. View

14.

Han M, Partin A, Pound C, Epstein J, Walsh P . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28(3):555-65. DOI: 10.1016/s0094-0143(05)70163-4. View

15.

Partin A, Carter H, Chan D, Epstein J, Oesterling J, Rock R . Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990; 143(4):747-52. DOI: 10.1016/s0022-5347(17)40079-6. View

16.

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S . Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009; 27(18):2924-30. DOI: 10.1200/JCO.2008.18.9563. View

17.

Zincke H, Oesterling J, Blute M, Bergstralh E, Myers R, Barrett D . Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994; 152(5 Pt 2):1850-7. DOI: 10.1016/s0022-5347(17)32399-6. View

18.

DAmico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969-74. DOI: 10.1001/jama.280.11.969. View

19.

Calais da Silva F, Bono A, Whelan P, Brausi M, Marques Queimadelos A, Martin J . Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009; 55(6):1269-77. DOI: 10.1016/j.eururo.2009.02.016. View

20.

Han M, Partin A, Piantadosi S, Epstein J, Walsh P . Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001; 166(2):416-9. View